Soleno Therapeutics, Inc. logo

Soleno Therapeutics, Inc.

Brand

0.0

Company overview

At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more information, please visit soleno.life.
Founded in 1999
Redwood City, California, USA
162 employees (11 in marketing)
soleno.life
0% recommend to a friend
0% positive business outlook

Salaries

Help build salary transparency at Soleno Therapeutics, Inc.

Share your compensation anonymously to see full data.

Contribute

People

Hiring activity

Open marketing jobs over time

2 open now

Headcount trend

Company growth over the last 12 months

Headcount +52.8% year over year

Funding

Total funding

$569.2M

Last raise

$200M

Post IPO Equity, 8 months ago

Funding history

Jul 2025

Post IPO Equity Soleno Therapeutics · $200M

Dec 2024

Post IPO Debt Soleno Therapeutics · $50M

May 2024

Post IPO Equity Soleno Therapeutics · $158.7M

Sep 2023

Post IPO Equity Soleno Therapeutics · $129M

Mar 2022

Post IPO Equity Soleno Therapeutics · $15M

Dec 2018

Post IPO Equity Soleno Therapeutics · $16.5M

Audience

Monthly website visitors
8.9K
Month over month0%
Quarter over quarter0%
Top sourceDirect (30.9%)
Ad budget per month$0.0
Average search rank49.2
Traffic source mix
Direct
30.9%
Search
21.9%
Social
7.8%
Referral
3.6%
Paid referral
0.7%

LinkedIn followers

Follower count and growth

Total followers

15.8K

12-mo growth

+82.9%

Monthly growth

+19.2%

News

Links

soleno.lifeLinkedInCrunchbase
Glassdoor